NPI: 1033196001 · RESEARCH TRIANGLE PARK, NC 27709 · Clinical Medical Laboratory · NPI assigned 12/29/2005
Authorized official WILLIAMS, KIMBERLY controls 20+ related entities in our dataset. Read more
| Authorized Official | WILLIAMS, KIMBERLY (VP) |
| NPI Enumeration Date | 12/29/2005 |
Other providers sharing the same authorized official: WILLIAMS, KIMBERLY
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 18,172 | $2.84M |
| 2019 | 47,785 | $5.32M |
| 2020 | 95,094 | $10.09M |
| 2021 | 108,286 | $10.76M |
| 2022 | 83,009 | $9.24M |
| 2023 | 106,300 | $7.75M |
| 2024 | 96,936 | $7.17M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 163,570 | 152,158 | $13.50M |
| 81229 | 25,968 | 23,636 | $10.94M | |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | 10,381 | 10,336 | $8.24M |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 47,551 | 46,323 | $5.09M |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | 18,625 | 18,509 | $3.38M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 34,716 | 34,468 | $2.18M |
| 88185 | 7,630 | 6,127 | $1.69M | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 9,202 | 9,137 | $905K |
| 88262 | 9,400 | 8,858 | $693K | |
| 88230 | 9,384 | 8,838 | $565K | |
| 88313 | 7,702 | 7,675 | $507K | |
| 86769 | 7,063 | 6,985 | $377K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 5,770 | 5,648 | $365K |
| 81206 | 6,484 | 5,972 | $360K | |
| 88342 | 3,747 | 3,686 | $349K | |
| 81374 | 5,075 | 5,057 | $331K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 6,259 | 6,176 | $316K |
| 81207 | 6,441 | 5,933 | $303K | |
| 81270 | 8,984 | 8,279 | $286K | |
| 88189 | 6,321 | 5,863 | $257K | |
| 88184 | 6,620 | 6,127 | $237K | |
| 81243 | 4,329 | 4,282 | $202K | |
| 88235 | 2,364 | 2,145 | $191K | |
| 88271 | 5,023 | 4,407 | $164K | |
| 81279 | 3,046 | 2,805 | $156K | |
| 88237 | 2,390 | 2,148 | $146K | |
| 81219 | 3,733 | 3,446 | $132K | |
| 81338 | 2,777 | 2,571 | $127K | |
| 88269 | 1,322 | 1,211 | $121K | |
| 81479 | Unlisted molecular pathology procedure | 1,618 | 1,306 | $111K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 631 | 630 | $108K |
| 81401 | 1,309 | 1,296 | $88K | |
| 88275 | 2,290 | 2,062 | $81K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 1,482 | 1,469 | $75K |
| 88274 | 2,510 | 2,069 | $70K | |
| 81402 | 1,012 | 933 | $63K | |
| 88173 | 972 | 909 | $49K | |
| 81403 | 1,096 | 983 | $46K | |
| 88289 | 2,460 | 2,280 | $41K | |
| 88280 | 1,820 | 1,680 | $27K | |
| 88233 | 384 | 356 | $27K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 214 | 214 | $21K |
| 88285 | 1,814 | 1,666 | $20K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 61 | 61 | $20K |
| 81381 | 191 | 190 | $19K | |
| 88261 | 152 | 135 | $18K | |
| 81256 | 297 | 296 | $16K | |
| 81241 | 297 | 295 | $13K | |
| 82668 | 1,319 | 1,217 | $11K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 123 | 122 | $10K |
| 88360 | 27 | 27 | $8K | |
| 81327 | 457 | 404 | $7K | |
| 81200 | 151 | 150 | $7K | |
| 81242 | 106 | 106 | $5K | |
| 81260 | 149 | 148 | $5K | |
| 81377 | 27 | 27 | $4K | |
| 81291 | 96 | 96 | $4K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 4,961 | 4,921 | $4K |
| 36415 | Collection of venous blood by venipuncture | 4,829 | 4,700 | $4K |
| 82106 | 457 | 426 | $4K | |
| 83521 | 63 | 63 | $4K | |
| 81273 | 86 | 80 | $3K | |
| 81422 | 14 | 14 | $3K | |
| 81240 | 110 | 110 | $2K | |
| 81209 | 106 | 106 | $2K | |
| 83883 | 312 | 308 | $2K | |
| 88112 | 2,285 | 2,142 | $2K | |
| 81257 | 43 | 43 | $2K | |
| 82105 | 395 | 361 | $2K | |
| 86038 | 542 | 524 | $2K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1,084 | 1,056 | $2K |
| 84443 | Thyroid stimulating hormone (TSH) | 6,775 | 6,727 | $2K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1,051 | 1,026 | $2K |
| 81290 | 38 | 38 | $2K | |
| 80053 | Comprehensive metabolic panel | 9,497 | 9,399 | $2K |
| 81330 | 38 | 38 | $2K | |
| 81251 | 38 | 38 | $1K | |
| 84410 | 25 | 24 | $1K | |
| 80061 | Lipid panel | 7,991 | 7,948 | $1K |
| 83036 | Hemoglobin; glycosylated (A1C) | 8,010 | 7,946 | $1K |
| 81210 | 16 | 14 | $1K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 185 | 183 | $1K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 160 | 88 | $917.69 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 973 | 969 | $678.14 |
| 85652 | 690 | 658 | $663.32 | |
| 82746 | 1,789 | 1,778 | $655.84 | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 7,899 | 7,796 | $641.23 |
| 81255 | 13 | 13 | $511.03 | |
| 84439 | 2,631 | 2,606 | $463.67 | |
| 85027 | 1,337 | 1,330 | $436.28 | |
| 82607 | 2,332 | 2,318 | $415.05 | |
| 81329 | 37 | 35 | $411.70 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 176 | 176 | $347.06 |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1,821 | 1,797 | $334.15 |
| 82728 | 921 | 906 | $267.56 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 112 | 112 | $240.00 |
| 86480 | 196 | 195 | $238.35 | |
| 86803 | 514 | 514 | $235.34 | |
| 80050 | General health panel | 193 | 188 | $188.06 |
| 83540 | 1,169 | 1,146 | $169.80 | |
| 87186 | 562 | 502 | $141.78 | |
| 82043 | 2,399 | 2,388 | $133.62 | |
| 87088 | 576 | 565 | $122.24 | |
| 85610 | 911 | 889 | $111.87 | |
| 86140 | 464 | 440 | $107.11 | |
| 81003 | 1,090 | 1,089 | $103.95 | |
| 83735 | 906 | 889 | $100.49 | |
| 84154 | 329 | 329 | $98.34 | |
| 83550 | 990 | 974 | $96.89 | |
| 80055 | 36 | 35 | $95.50 | |
| 87081 | 80 | 79 | $93.34 | |
| 82375 | 14 | 13 | $82.52 | |
| 81244 | 18 | 15 | $78.48 | |
| 84702 | 166 | 152 | $74.19 | |
| 85730 | 704 | 690 | $63.13 | |
| 82947 | 266 | 265 | $52.33 | |
| 80074 | 465 | 463 | $48.11 | |
| 80048 | Basic metabolic panel (calcium, ionized) | 524 | 521 | $47.57 |
| 82784 | 56 | 42 | $44.31 | |
| 82570 | 2,191 | 2,185 | $43.58 | |
| 82670 | 74 | 74 | $38.78 | |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | 342 | 330 | $35.75 |
| 86200 | 15 | 15 | $24.43 | |
| 84146 | 16 | 16 | $23.09 | |
| 86431 | 220 | 212 | $21.61 | |
| 86235 | 13 | 13 | $14.01 | |
| 87077 | 246 | 239 | $11.73 | |
| 83001 | 27 | 27 | $9.62 | |
| 83002 | 59 | 59 | $9.59 | |
| 83516 | 16 | 16 | $9.01 | |
| 82677 | 112 | 102 | $5.69 | |
| 82950 | 27 | 27 | $3.85 | |
| 86336 | 112 | 102 | $3.68 | |
| 81001 | 2,966 | 2,949 | $2.84 | |
| 85014 | 16 | 16 | $1.92 | |
| 85018 | 15 | 15 | $1.92 | |
| 82248 | 381 | 381 | $0.00 | |
| 87999 | 172 | 172 | $0.00 | |
| 83970 | 317 | 316 | $0.00 | |
| 82274 | 299 | 296 | $0.00 | |
| 84550 | 1,086 | 1,081 | $0.00 | |
| 84450 | 70 | 70 | $0.00 | |
| 84100 | 569 | 563 | $0.00 | |
| 87535 | 15 | 15 | $0.00 | |
| 86900 | 12 | 12 | $0.00 | |
| 87338 | 28 | 28 | $0.00 | |
| 84156 | 174 | 172 | $0.00 | |
| 82565 | 321 | 321 | $0.00 | |
| 82310 | 131 | 131 | $0.00 | |
| 84481 | 389 | 384 | $0.00 | |
| 84403 | 402 | 397 | $0.00 | |
| 83695 | 25 | 25 | $0.00 | |
| 80076 | 36 | 36 | $0.00 | |
| 84295 | 95 | 95 | $0.00 | |
| 84155 | 80 | 79 | $0.00 | |
| 84520 | 186 | 186 | $0.00 | |
| 82977 | 94 | 94 | $0.00 | |
| 82247 | 78 | 78 | $0.00 | |
| 82627 | 12 | 12 | $0.00 | |
| 84305 | 12 | 12 | $0.00 | |
| 87150 | 14 | 13 | $0.00 | |
| 83655 | 25 | 25 | $0.00 | |
| 82652 | 12 | 12 | $0.00 | |
| 84165 | 14 | 13 | $0.00 | |
| 86696 | 15 | 15 | $0.00 | |
| 87340 | 533 | 531 | $0.00 | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 403 | 403 | $0.00 |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | 275 | 275 | $0.00 |
| 84153 | 1,359 | 1,352 | $0.00 | |
| 86704 | 291 | 291 | $0.00 | |
| 86592 | 1,021 | 1,018 | $0.00 | |
| 84075 | 56 | 56 | $0.00 | |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | 322 | 322 | $0.00 |
| 84436 | 576 | 575 | $0.00 | |
| 86706 | 315 | 314 | $0.00 | |
| 83880 | 213 | 208 | $0.00 | |
| 83615 | 238 | 232 | $0.00 | |
| 86376 | 54 | 53 | $0.00 | |
| 84480 | 96 | 96 | $0.00 | |
| 84402 | 116 | 116 | $0.00 | |
| 87522 | Neg quan hep c or qual rna | 32 | 31 | $0.00 |
| 84479 | 207 | 206 | $0.00 | |
| 82040 | 77 | 77 | $0.00 | |
| 82435 | 125 | 125 | $0.00 | |
| 84132 | 80 | 80 | $0.00 | |
| 86225 | 14 | 14 | $0.00 | |
| 82533 | 12 | 12 | $0.00 | |
| 86695 | 13 | 13 | $0.00 | |
| G0475 | Hiv antigen/antibody, combination assay, screening | 12 | 12 | $0.00 |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 69 | 69 | $0.00 |
| 86141 | 13 | 13 | $0.00 | |
| 86701 | 13 | 13 | $0.00 | |
| 83090 | 12 | 12 | $0.00 | |
| 80051 | 14 | 14 | $0.00 | |
| 88141 | 40 | 40 | $0.00 | |
| 87070 | 12 | 12 | $0.00 | |
| 87529 | 13 | 13 | $0.00 | |
| 86702 | 13 | 13 | $0.00 |